The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Herpes Zoster
- Sponsor
- University of Tennessee
- Enrollment
- 205
- Locations
- 3
- Primary Endpoint
- To assess the effect of a pharmacist-driven immunization campaign on the rate of Zostavax immunizations in three separate community pharmacy settings
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to determine whether pharmacist-driven patient interventions can have an effect on the number of herpes zoster (Zostavax) vaccinations given in a community pharmacy setting.
Detailed Description
Several studies exist documenting the perception and satisfaction of patients receiving immunizations from pharmacists, as well as the effects of pharmacist involvement in advocating and administering vaccinations. The most well documented studies have been conducted in hospital settings. Undoubtedly, there is enormous opportunity for the community pharmacist to identify potential vaccine recipients, advocate immunization and administer said immunizations to their established patient populations. However, there is a lack of concentrated study in the implementation of immunization services in the community setting and their effects. The investigators intend to evaluate the intervention of pharmacists in an immunization program and the resulting changes in immunization rates.
Investigators
Eligibility Criteria
Inclusion Criteria
- •men and women aged 60 or older without contraindications for the herpes zoster vaccination
- •patients who have already experienced one or more episodes of herpes zoster infection were considered for vaccine receipt and study inclusion secondary to CDC ACIP recommendations
Exclusion Criteria
- •Patients aged \< 60 years
- •Anyone who has previously received the herpes zoster vaccine
- •Anyone with an allergy to neomycin, gelatin or any other component of the vaccine
- •Anyone receiving a live vaccine within 4 weeks
- •Anyone with a compromised or weakened immune systems such as those receiving radiation, corticosteroids, or those with HIV/AIDS, cancer in the lymph, bone or blood systems
- •Pregnant women or those in close contact with a pregnant woman
Outcomes
Primary Outcomes
To assess the effect of a pharmacist-driven immunization campaign on the rate of Zostavax immunizations in three separate community pharmacy settings
Time Frame: 2 months
Secondary Outcomes
- To evaluate the relative efficacy of specific interventions on the rate of herpes zoster vaccinations(2 months)
- To evaluate the perception of patients receiving the herpes zoster vaccination as to the role of pharmacists as immunizers(2 months)